Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a primary brain tumor that has come back, where no curative treatment is available, OR a solid tumor that has returned or stopped responding to treatment, where no curative option exists and at least two lines of prior treatment have been tried.
• People whose tumor can be measured using standard medical imaging criteria (specific measurement criteria apply depending on whether the tumor is in the brain or elsewhere in the body — confirm with trial site).
• People who are expected to live for more than 12 weeks.
• People who have previously been treated with radiation, chemotherapy, or a combination of both.
• People who are between 6 and 29 years old (inclusive).
• People who are able to swallow whole pills.
• People whose blood counts and organ function fall within acceptable ranges, as assessed by blood tests (confirm specific values with trial site).
• People with a performance score of 60 or higher on standard medical scales, meaning they are able to carry out some daily activities (confirm with trial site).
• People of childbearing potential, and their partners, who are willing to use two forms of contraception (including at least one barrier method) throughout the study period, and who agree to immediately inform their treating doctor if pregnancy occurs or is suspected.
• People, or their parents or legal guardians, who are able to understand and willing to sign a formal consent document approved by an ethics review board.

Who may not be able to join:

• People who are currently using, or have previously used, a class of diabetes medications called SGLT2 inhibitors or thiazolidinediones.
• People currently taking high-dose dexamethasone (a steroid) at more than 4 mg per day, or who have not been on a stable or reducing dose for at least 7 days before starting the study drug.
• People with a history of another cancer, unless all treatment for that cancer was completed at least 2 years ago with no sign of return, or the cancer was a locally treated skin cancer of a specific type (confirm with trial site).
• People with Type 1 diabetes or who are currently receiving insulin treatment.
• People who have had a stroke or a mini-stroke (transient ischemic attack) within the last 5 years.
• People with a blood sugar control reading (HbA1c) above 8.5%.
• People who are currently taking part in another clinical trial involving an experimental treatment.
• People who have had a significant allergic reaction to medications that are chemically similar to the study drug, dapagliflozin.
• People with certain uncontrolled health conditions, including active infection, heart failure, unstable chest pain, irregular heart rhythms, poor circulation in the limbs, a dangerous chemical imbalance called ketoacidosis, severe kidney disease, low blood pressure causing symptoms, or frequent urinary tract or yeast infections.
• People who are pregnant or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days before starting the study drug.
• People living with HIV whose immune cell count (CD4+ T-cells) is below 350 cells/mcL, or who have had a serious HIV-related infection within the past 12 months.

Important: Always verify eligibility with the trial site directly before applying.